Linked Life Data

18538178

Source:http://linkedlifedata.com/resource/pubmed/id/18538178

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3 Suppl 3
pubmed:dateCreated
2008-6-9
pubmed:abstractText
Vinflunine is a novel microtubule inhibitor of the vinca alkaloid class currently in development for the treatment of advanced transitional cell carcinoma of the urothelium (TCCU) and other solid tumors. This review summarizes the clinical activity of vinflunine as a single agent or in combination with other antineoplastic drugs. Vinflunine is active against a variety of tumor types, including advanced TCCU, metastatic breast cancer, advanced non-small cell lung cancer, and malignant pleural mesothelioma. It has a manageable and noncumulative toxicity profile, and its specific mechanism of action has been linked to a reduced potential for peripheral sensory neuropathy. The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
35
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S34-43
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.
pubmed:affiliation
Medical Oncology Service, University Hospital Del Mar, Paseo Maritimo 25-29, Barcelona, Spain. jbellmunt@imas.imim.es
pubmed:publicationType
Journal Article, Review